The U.S. Food and Drug Administration (FDA) approved a supplemental application for Keytruda (pembrolizumab) on July 30, 2019. This approval, identified as BLA 125514 S-56, specifically pertains to the efficacy of the drug, indicating an update or expansion of its demonstrated effectiveness.
Background
Keytruda (pembrolizumab) is a well-known immunotherapy developed and sponsored by Merck Sharp Dohme. As an established treatment, it has received multiple approvals for various indications. Supplemental approvals, such as this one, typically build upon existing knowledge of a drug's profile, often expanding its use to new patient populations, different stages of a disease, or providing further substantiation of its efficacy in previously approved settings. This particular supplemental approval focused on efficacy, reinforcing the drug's therapeutic benefits.
What this means
This supplemental approval for Keytruda (pembrolizumab) on July 30, 2019, signifies an important update to its prescribing information. While the specific details of the new indication or patient population are not provided in the summary data, supplemental efficacy approvals generally mean that the FDA has reviewed additional data demonstrating the drug's effectiveness for a new use, or has confirmed its efficacy for an existing use with new evidence. This allows clinicians to consider Keytruda for an expanded group of patients or conditions, or provides stronger support for its current applications. Healthcare providers and researchers should consult the full updated prescribing information from the FDA to understand the precise scope of this efficacy approval and its implications for patient care.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for supplemental application BLA 125514 S-56 for Keytruda (pembrolizumab) was recorded on July 30, 2019, and is publicly accessible via accessdata.fda.gov.